SCHEMBL931815

SCHEMBL931815

O=C(O)CCOCCOCCOCCO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
TSHR P16473 5/20 0.53
MAPK1 P28482 1/20 0.53
CAMK2A Q9UQM7 1/20 0.43
LMNA P02545 3/20 0.40
GPR84 Q9NQS5 1/20 0.40
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
ALKBH5 Q6P6C2 1/20 0.40
SUCNR1 Q9BXA5 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
PMP22 Q01453 2/20 0.39
BLM P54132 1/20 0.39
HSD17B10 Q99714 1/20 0.39
THRB P10828 1/20 0.39
HTT P42858 1/20 0.39
MAPT P10636 1/20 0.39
ALDH1A1 P00352 2/20 0.38
SLC22A6 Q4U2R8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20840356 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1CAMK2A
SCHEMBL29282163 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1CAMK2A
SCHEMBL2555371 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1CAMK2A
SCHEMBL4588453 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1CAMK2A
SCHEMBL19402669 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1CAMK2A
SCHEMBL16329219 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1CAMK2A
SCHEMBL22445115 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1CAMK2A
SCHEMBL22445005 1.00 MEN1 (0.58) MEN1KMT2ATSHRMAPK1CAMK2A
Hydrochloric Acid SCHEMBL28335348 0.97 MEN1 (0.55) MEN1KMT2ATSHRMAPK1CAMK2A
SCHEMBL46587 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250235543-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2025-07-24 US disclosed
EP-4374877-A2 PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-29 EP disclosed
EP-3928779-B1 PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-03-06 EP disclosed
EP-4319817-A1 PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF Rakuten Medical, Inc. (US) 2024-02-14 EP disclosed
CN-115058280-B Lubricating oil composition and method for producing same 株式会社力森诺科 2024-02-13 CN disclosed
US-20230399515-A1 PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF Rakuten Medical, Inc. 2023-12-14 US disclosed
US-20230399515-A1 PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF Rakuten Medical, Inc. 2023-12-14 US disclosed
US-11786602-B2 ASH1L degraders and methods of treatment therewith THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-17 US disclosed
US-20230218766-A1 SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX THE NOGUCHI INSTITUTE (JP) 2023-07-13 US disclosed
US-11633490-B2 2023-04-25 US disclosed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 US disclosed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 US disclosed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 US disclosed
EP-2448929-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-05-09 EP disclosed
WO-2011001052-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-06 WO disclosed
US-20100029903-A1 Polypeptide Protracting Tags NOVO NORDISK A/S (DK) 2010-02-04 US disclosed
EP-1963343-A1 POLYPEPTIDE PROTRACTING TAGS Novo Nordisk A/S (DK) 2008-09-03 EP disclosed
CN-100387425-C Sheet-form layered structure with attractive apperance and utilziation thereof TEIJIN CHEMICALS LTD (JP) 2008-05-14 CN disclosed
WO-2007068718-A1 POLYPEPTIDE PROTRACTING TAGS NOVO NORDISK A/S (DK) 2007-06-21 WO disclosed
CN-1392834-A Sheet-like layered structure having high appearance and use thereof TEIJIN CHEMICALS LTD (JP) 2003-01-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF ERG28, CARS1, FOLH1 MEN1 486/4885KMT2A 3995/4885TSHR 4077/4885
US-20230218766-A1 SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX FCGRT, HBZ, FUT4 MEN1 2580/4885KMT2A 1510/4885TSHR 173/4885
US-11786602-B2 ASH1L degraders and methods of treatment therewith ASH1L, ASH2L, DOT1L MEN1 3210/4885KMT2A 56/4885TSHR 3845/4885
US-20100029903-A1 Polypeptide Protracting Tags LAS1L, SEC16A, PHAX MEN1 2188/4885KMT2A 3483/4885TSHR 849/4885
US-20250235543-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, TP53BP1 MEN1 2854/4885KMT2A 2300/4885TSHR 3311/4885
US-11633490-B2 ASH1L, ASH2L, STUB1 MEN1 3261/4885KMT2A 108/4885TSHR 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.